FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
